CCM
CTXR icon

Conway Capital Management’s Citius Pharmaceuticals CTXR Stock Holding History

Conway Capital Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-800
Closed -$30.8K – 60
2021
Q4 		$30.8K Hold
800
– – 0.02% 62
2021
Q3 		$40.6K Hold
800
– – 0.03% 69
2021
Q2 		$69.6K Sell
800
-400
-33% -$24K 0.05% 72
2021
Q1 		$53.4K Buy
+1,200
New +$47.8K 0.04% 73

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Conway Capital Management's CTXR Position: Q1 2022 in Review

Conway Capital Management sold out of Citius Pharmaceuticals (CTXR) in Q1 2022, closing a stake of 800 shares — an estimated $30.8K sold.

Conway Capital Management first reported a position in CTXR in Q1 2021 and held it in 4 quarters. The position peaked at $69.6K in Q2 2021. 76 funds tracked by Wall St. Rank hold CTXR as of Q1 2022.

  • Conway Capital Management reported no remaining Citius Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Conway Capital Management sold 800 Citius Pharmaceuticals shares in Q1 2022, an estimated $30.8K.
  • Conway Capital Management first reported a position in Citius Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • Conway Capital Management's Citius Pharmaceuticals position peaked at $69.6K in Q2 2021.
  • 76 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2022.

Based on Conway Capital Management's 13F filing for Q1 2022, filed 3 Dec 2024.